Amyloidosis: Novel Treatments Could Improve Poor Outcomes
Systemic light chain amyloidosis is a clonal plasma cell disorder that can lead to end-organ dysfunction, with no approved treatment in the relapsed/refractory setting. Given this challenging clinical situation, two studies of novel therapies for this disease reported at the 2026 ASCO Annual Meeting were met with particular enthusiasm.